Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details)

v3.24.2.u1
Commitments and Contingencies (Details)
₪ in Thousands, $ in Thousands
6 Months Ended
Jan. 18, 2024
USD ($)
Mar. 31, 2023
USD ($)
Mar. 31, 2023
ILS (₪)
Jun. 23, 2022
USD ($)
Mar. 31, 2022
USD ($)
Mar. 31, 2022
ILS (₪)
Aug. 31, 2021
USD ($)
Aug. 31, 2021
ILS (₪)
Jun. 30, 2024
USD ($)
Jun. 30, 2024
ILS (₪)
Jun. 30, 2024
ILS (₪)
Commitments and Contingencies [Line Items]                      
Manufacturing capabilities             $ 1,778 ₪ 5,737      
Fund approved budget             50.00% 50.00%      
Received amount                 $ 395   ₪ 1,365
Aggregate budget   $ 3,164 ₪ 11,283   $ 4,094 ₪ 13,004          
Percentage of approved budgets   30.00% 30.00%   30.00% 30.00%          
Total approved grants                 9,353 ₪ 32,068  
Grant receivable                 8,003   27,423
Royalty expense                 7,413    
Contingent obligation                 8,124    
Receive fees       $ 1,411              
Installment amount $ 211                    
Cystic Fibrosis Product [Member]                      
Commitments and Contingencies [Line Items]                      
Received amount                 768 ₪ 2,783  
Israel Innovation Authority [Member]                      
Commitments and Contingencies [Line Items]                      
Received amount                 $ 577   ₪ 1,912
Minimum [Member]                      
Commitments and Contingencies [Line Items]                      
Royalties rate                 3.00% 3.00%  
Maximum [Member]                      
Commitments and Contingencies [Line Items]                      
Royalties rate                 3.50% 3.50%